Point-of-Care PCR Panel Delivers Vaginitis Results in 20 Minutes

Vaginitis is a frequent cause of genital discomfort and can result from bacterial vaginosis, vulvovaginal candidiasis, or trichomoniasis. However, traditional diagnostic methods may be subjective or lack sensitivity, contributing to misdiagnosis, delayed treatment, and inappropriate therapy in routine care. As a result, only about half of women diagnosed with vaginitis by non-molecular testing receive appropriate treatment. To improve diagnostic accuracy and support timely clinical decisions, a new point-of-care multiplex polymerase chain reaction (PCR) test now reports eight results, including bacterial vaginosis, yeast, and parasitic pathogens, from a single swab in about 20 minutes

BioMérieux has submitted a Dual 510(k)/CLIA Waiver application to the U.S. Food and Drug Administration (FDA) for the BIOFIRE SPOTFIRE Vaginitis (VG) Panel. The automated, multiplex PCR assay is designed for use directly at the point of care and represents the company’s first step into women’s and sexual health testing within its point-of-care portfolio. The panel runs on the BIOFIRE SPOTFIRE System, a modular instrument intended to fit varied healthcare settings.

image: The BIOFIRE SPOTFIRE VG Panel is designed to align with a typical patient visit, producing eight results from a single swab in about 20 minutes (Photo courtesy of BioMérieux)

The BIOFIRE SPOTFIRE VG Panel is designed to align with a typical patient visit, producing eight results from a single swab in about 20 minutes. Its results include bacterial vaginosis as well as yeast and parasitic pathogens, enabling a syndromic approach to vaginitis testing at the point of care. By delivering rapid, actionable information, the test is intended to support timely treatment decisions while providing a clearer and more dignified diagnostic experience for patients presenting with vaginitis symptoms.

bioMérieux has filed the panel for both 510(k) clearance and CLIA waiver, which would permit use by non-laboratory professionals at the point of care. Following the U.S. submission, the panel is also expected to be submitted in the European Union as a Class C Near Patient Test for CE marking under the In Vitro Diagnostic Regulation. 

The company’s broader strategy emphasizes expanding syndromic testing into point‑of‑care environments so that healthcare professionals can deliver actionable results during a single visit and strengthen the role of diagnostics in managing infectious diseases.

“Not only are the symptoms of vaginitis disruptive and painful, the underlying condition is also associated with other health conditions, including pelvic inflammatory disease, cervical cancer, adverse birth outcomes, and secondary infections. bioMérieux is proud to bring a better diagnostic solution to patients, which can guide healthcare practitioners in prescribing targeted treatment to more quickly alleviate symptoms and potentially reduce the risk of other negative health consequences,” said Dr. Charles K. Cooper, Executive Vice President, Chief Medical Officer, bioMérieux.

“Today, there is a clear and persistent gap in vaginitis diagnostics — between the need for accurate, comprehensive testing and the reality of delayed or incomplete results in clinical practice. With the BIOFIRE SPOTFIRE Vaginitis Panel, bioMérieux is addressing this gap by bringing fast, syndromic molecular testing directly to the point-of-care setting, enabling healthcare practitioners to move from uncertainty to actionable answers within a single patient visit. This is not just an incremental improvement, it’s a strategic step toward closing a long-standing diagnostics gap in women’s and sexual health, fundamentally improving both clinical decision-making and the patient experience,” added Jennifer Zinn, Executive Vice President, Clinical Operations, at bioMérieux.